Compare Koninklijke Philips NV (PHG) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Koninklijke Philips NV vs Smith & Nephew plc — how do they compare? Koninklijke Philips NV trades at $26.3 (market cap $25.89B), while Smith & Nephew plc trades at $29.95 (market cap $12.71B). The key difference: Koninklijke Philips NV is far larger — about 2× Smith & Nephew plc's market cap, and Koninklijke Philips NV pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| PHG | SNN | |
|---|---|---|
Market Cap | $25.89B | $12.71B |
Sector | Health | Health |
52-Week High | $32.91 | $38.70 |
52-Week Low | $25.02 | $28.73 |
Enterprise Value | $32.18B | $15.48B |
Dividend Yield | 3.81% | 2.59% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Koninklijke Philips NV
Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
